Holen Sie sich die Stockscreener-App
11.45
5.72%
0.62
Schlusskurs vom Vortag:
$10.83
Offen:
$10.82
24-Stunden-Volumen:
81,639
Relative Volume:
1.93
Marktkapitalisierung:
$23.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.34M
KGV:
-4.2415
EPS:
-2.6995
Netto-Cashflow:
$-10.54M
1W Leistung:
+0.00%
1M Leistung:
-22.64%
6M Leistung:
+2.32%
1J Leistung:
+137.89%
1-Tages-Spanne:
$10.52
$12.28
1-Wochen-Bereich:
$10.45
$12.60
52-Wochen-Spanne:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
11.45 | 22.57M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway - TipRanks
Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path - Stock Titan
Polyrizon stock surges on human study for allergy blocker By Investing.com - Investing.com South Africa
Polyrizon Ltd. Enters Agreement With European University Medical Center And Clinical Research Organization For Human Study Of NASARIX? - marketscreener.com
Polyrizon initiates nasal residence time study for allergy blocker - Investing.com
Polyrizon initiates nasal residence time study for allergy blocker By Investing.com - Investing.com Canada
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - The Manila Times
How long can a nasal allergy blocker stay put? New human study aims to find out - Stock Titan
Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) moves ahead on European nasal drug patent - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon Marches on European Patent - Baystreet.ca
Polyrizon receives European patent application publication - Investing.com
Polyrizon receives European patent application publication By Investing.com - Investing.com India
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - The Manila Times
Polyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery Technology - Quiver Quantitative
Polyrizon Sets July 13, 2026 AGM to Vote on Board, Pay and Auditor Mandates - The Globe and Mail
Polyrizon schedules annual shareholder meeting for July 13 By Investing.com - Investing.com Canada
Polyrizon Secures Three Key U.S. Sites for NASARIX Allergy Trial - TipRanks
Polyrizon schedules annual shareholder meeting for July 13 - Investing.com
Polyrizon (PLRZ) 2026 AGM to vote on compensation policy, major RSU grants and Deloitte re-appointment - Stock Titan
Polyrizon (Nasdaq: PLRZ) signs 3 key U.S. sites for NASARIX allergy trial - Stock Titan
Polyrizon signs two more U.S. sites for allergy trial By Investing.com - Investing.com South Africa
Polyrizon signs two more U.S. sites for allergy trial - Investing.com
Polyrizon Ltd. Expands Clinical Trial Network for NASARIX™ Allergy Blocker with Two New U.S. Sites - Quiver Quantitative
New nasal gel trial to block airborne seasonal allergens in U.S. - Stock Titan
Polyrizon extends exclusivity for 51% Arrow Aviation acquisition - scanx.trade
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks By Investing.com - Investing.com Nigeria
Polyrizon Extends Exclusivity on Proposed 51% Acquisition of Arrow Aviation - TipRanks
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks - Investing.com
Polyrizon (NASDAQ: PLRZ) prolongs Arrow Aviation 51% stake talks - Stock Titan
Polyrizon Shares Flat After Delay in New Filing Near Highs - Bez Kabli
Polyrizon Appoints Veteran Entrepreneur Ami Oren to Board of Directors - The Globe and Mail
Polyrizon Ltd. (PLRZ) Posts Modest Gain as Stock Consolidates Near Support LevelsETH Profile - The Legal Advocate
Polyrizon (PLRZ) appoints entrepreneur Ami Oren as new Class I director - Stock Titan
Polyrizon Ltd. (PLRZ) Soars Over 20%: Key Levels and Potential ScenariosBollinger Squeeze - The Legal Advocate
Polyrizon Ltd. (PLRZ) Surges Over 20% — Key Resistance Level in FocusOpen Trading Community - Newser
PLRZ Technical Analysis | Trend, Signals & Chart Patterns | POLYRIZON LTD (NASDAQ:PLRZ) - ChartMill
Number of shareholders of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TipRanks
Polyrizon signs first clinical trial agreement for allergy drug By Investing.com - Investing.com India
Polyrizon Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Trial - geneonline.com
Polyrizon signs first clinical trial agreement for allergy drug - Investing.com
Polyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker Trial - TipRanks
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - The Manila Times
Polyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in Texas - Quiver Quantitative
Polyrizon (Nasdaq: PLRZ) signs first U.S. clinical site for NASARIX PL-14 allergy study - Stock Titan
Nasal spray to block airborne allergens heads to first U.S. allergy trial site - Stock Titan
TradingKey - TradingKey
Polyrizon develops nasal barrier tech to block multiple respiratory viruses amid rising viral threats - Pluang
Nasal barrier tech: how Polyrizon wants to plug gaps before vaccines - Stock Titan
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Polyrizon Ltd-Aktie (PLRZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Carmel Liron | Director |
Mar 31 '26 |
Sale |
12.36 |
942 |
11,643 |
3,127 |
| Adler Oz | Director |
Mar 31 '26 |
Sale |
12.05 |
3,292 |
39,669 |
19,850 |
| Carmel Liron | Director |
Mar 30 '26 |
Sale |
11.00 |
100 |
1,100 |
4,069 |
| Izraeli Tomer | Chief Executive Officer |
Mar 30 '26 |
Sale |
10.90 |
3,900 |
42,510 |
32,012 |
| Turgeman Tidhar | Chief Technology Officer |
Mar 30 '26 |
Sale |
10.90 |
2,917 |
31,795 |
17,518 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):